GENMAB A/S
GMAB · XNASCIK 1434265fmd_1AKS8PVHYAZN6YSSADNQ7KCTMZManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2017 to Dec 31, 2025, 16 periods
| Line item | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|---|---|
| Total revenues | 2,365 | 3,025 | 5,366 | 10,111 | 8,417 | 14,505 | 16,474 | 21,526 |
| Cost of revenue | – | – | – | – | – | – | 226 | 985 |
| Gross profit | – | – | – | – | – | – | 16,248 | 20,541 |
| Research and development | 874 | 1,431 | 2,386 | 3,137 | 4,181 | 5,562 | 7,630 | 9,748 |
| Selling, general and administrative | – | – | 342 | 661 | 1,283 | 2,676 | 3,297 | 3,790 |
| Operating income | 1,344 | 1,380 | 2,638 | 6,313 | 2,953 | 6,267 | 5,321 | 6,703 |
| Interest expense | 352 | 11 | 7 | 1,558 | 702 | 2,511 | 1,624 | 1,977 |
| Income before taxes | 1,064 | 1,612 | 2,859 | 5,904 | 3,918 | 6,945 | 5,637 | 9,164 |
| Income tax expense | (40) | 140 | 693 | 1,146 | 961 | 1,493 | 1,285 | 1,320 |
| Net income from continuing operations | 1,104 | 1,472 | 2,166 | 4,758 | 2,957 | 5,452 | 4,352 | 7,844 |
| Net income | 1,104 | 1,472 | 2,166 | 4,758 | 2,957 | 5,452 | 4,352 | 7,844 |